Stockscreener 앱 받기
1.03
3.74%
-0.04
시간 외 거래:
1.02
-0.01
-0.97%
전일 마감가:
$1.07
열려 있는:
$1.07
하루 거래량:
1.39M
Relative Volume:
1.11
시가총액:
$194.60M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-0.6319
EPS:
-1.63
순현금흐름:
$-193.47M
1주 성능:
-24.82%
1개월 성능:
-26.95%
6개월 성능:
-41.31%
1년 성능:
+113.91%
1일 변동 폭
$1.02
$1.09
1주일 범위
$1.02
$1.375
52주 변동 폭
$0.4227
$1.928
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| NKTR | 1.03 | 194.60M | 90.12M | -276.06M | -193.47M | -1.63 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Nektar presents preclinical data on NKTR-422 at ACR conference - TipRanks
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - Kilgore News Herald
Eventide Asset Management's Strategic Acquisition of Nektar Ther - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Nektar Therapeutics - GuruFocus.com
Multiple Catalysts Ahead For Nektar Therapeutics (NASDAQ:NKTR) - Seeking Alpha
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance
Nektar Therapeutics to sell Alabama facility to Ampersand - MSN
NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC - Targeted Oncology
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Canada Finance
Nektar Therapeutics (NASDAQ:NKTR) Q3 2024 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Nektar Therapeutics progresses with key clinical studies By Investing.com - Investing.com UK
Nektar Therapeutics (NKTR) Quarterly 10-Q Report - Quartz
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance
Nektar reports NKTR-255 boosts lymphocyte recovery By Investing.com - Investing.com Australia
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook - Yahoo Finance
Nektar: Q3 Earnings Snapshot - The Washington Post
Nektar Therapeutics Reports Stable Q3 Earnings for 2024 - TipRanks
Nektar Therapeutics Q3 2024 Earnings: Revenue Surpasses Estimate - GuruFocus.com
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Nektar: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c - StreetInsider.com
Nektar Therapeutics Narrows Losses, Sells Manufacturing Facility for $90M in Q3 | NKTR Stock News - StockTitan
Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Nektar releases promising phase 2 results for NKTR-255 in lymphopenia - MSN
Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more - MM+M Online
Nektar reports NKTR-255 boosts lymphocyte recovery - Investing.com
Nektar Therapeutics (NKTR) and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 - StreetInsider.com
Nektar's NKTR-255 Shows Breakthrough Results in Cancer Treatment Study with MD Anderson | NKTR Stock News - StockTitan
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook By GuruFocus - Investing.com Canada
Nektar Therapeutics to Present at UBS and Piper Sandler Healthcare Conferences | NKTR Stock News - StockTitan
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale - Yahoo Finance
Ampersand’s Acquisition of a Nektar’s Manufacturing Facility and Reagent Supply Business - Global Legal Chronicle
Nektar sells its PEGylation reagent manufacturing business - The Pharma Letter
Nektar divests manufacturing site and reagent arm for $90M - Endpoints News
Nektar announces agreement to sell Alabama manufacturing facility and reagent supply business - MSN
NKTRNektar Therapeutics Latest Stock News & Market Updates - StockTitan
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Benzinga
Nektar pads wallet with $90M manufacturing plant sale to Ampersand - FiercePharma
Nektar divests Alabama facility to Ampersand for $90 million By Investing.com - Investing.com Canada
Nektar Therapeutics Sells Manufacturing Facility for $90M - TipRanks
Nektar divests Alabama facility to Ampersand for $90 million - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Piper Sandler - MarketBeat
Nektar Therapeutics (NKTR) to Sell Commercial PEGylation Reagent Manufacturing Business in Alabama - StreetInsider.com
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama - StockTitan
Piper Sandler Starts Nektar Therapeutics (NKTR) at Overweight - StreetInsider.com
Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics for $90 million. - Marketscreener.com
Nektar Therapeutics (NKTR) Stock Surges Amidst Mixed Financials - GuruFocus.com
Nektar Therapeutics (NKTR) Scheduled to Post Earnings on Thursday - MarketBeat
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets - Longview News-Journal
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):